About Conference
The 2nd Annual summit on
Tuberculosis and Lung disease will be held in Atlanta, USA during July
16-17, 2018. It will bring together world-class pulmonologist, scientists and
professors to discuss strategies for disease remediation for TB & lung
diseases in this conference. Annual summit on Tuberculosis is designed to
provide a diverse and current education that will keep medical professionals up
to date on issues affecting the diagnosis, treatment of respiratory disorders
and prevention.
The
conference theme "A new way to battle with Tuberculosis and Lung disease"
that focuses to share novel approaches related to the field and exploring the
challenges concerning excellence in TB research and advancements.
2nd Annual summit on
Tuberculosis and Lung disease is an extraordinary event designed for TB
experts and international medical health professionals to facilitate the
dissemination and application of research findings related to TB and all the
associated research areas. The conference invites participants from
universities, clinical research institutions and diagnostic companies to share
their research experiences on all aspects of this rapidly expanding field and
thereby, providing a showcase of the latest techniques.
Scope and importance:
Our aims
to provide tuberculosis physicians, specialists, nurses, technologists and
anyone professionally involved in respiratory disease with an opportunity to
learn about the complexity of the disease, discuss interventional procedures,
look at new and advanced TB practices and their efficiency and efficacy in the
treatment of various cases, and understand local realities and practical
constraints in improving patient-care.
Why to attend??
With
people across the globe focused on finding a few solutions concerning TB and
lung diseases, this is the best platform to meet the eminent personalities of
respiratory care. This scientific stage will allow the researcher to showcase
their research work through presentations and have a chance to gain knowledge
about the current situation of lung disease treatment and receive name
recognition at this 2-day event.
Greatest achievements in the field of TB:
The great
achievement in lowering tuberculosis rates during the last decades of the 20th
century are secondary to the extraordinary advances made in the understanding
of basic respiratory science and in the enlargement of new diagnostic and
therapeutic techniques. The most important cardiologic developments and
discoveries of the last century are Multidrug-resistant TB (MDR-TB); first-line
and second-line anti-TB drugs; DOTS (directly observed treatment-short course)
therapy and Short course chemotherapy (SCC); “Stop TB” strategy; RNTCP (revised national TB control program). The development
and widespread implementation of vaccination against TB ranks one amongst man’s
greatest achievements.
Target Audience:
Pulmonologist
Lung
cancer Surgeons
Scientists
and Researchers
Medicinal
Practitioner
University
Professors
Lung
& respiratory associations and their members
Tuberculosis
Societies and their members
Founders
and Employees of health-related companies
Experts
of TB control Program
Medicine,
TB and pharma institutes
Training
Institutes
Physicians
interested in the latest advances and techniques
Research
Scholars and Students
Pharma
Companies
Allied Academic Publication is an
amalgamation of several esteemed academic and scientific associations known for
promoting scientific temperament. Established in the year 1997, Andrew John
Publishing Group is a specialized Medical publisher that operates in
collaboration with the association and societies. This publishing house has been built on the
base of esteemed academic and research institutions including The College of
Audiologists and Speech Language Pathologists of Ontario(CASLPO), The
Association of Public Safety Communications Officials of Canada (APCO), The
Canadian Vascular Access Association (CVAA), The Canadian Society of Internal
Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography
Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian
Association of Neurophysiologic Monitoring (CANM).
Welcome Message
On behalf
of Allied academics we are glad to invite you to 2nd Annual summit on Tuberculosis and
Lung disease held at Atlanta,
USA during 16-17 July 2018. Our conference proceeds with theme “A new way to battle with Tuberculosis and
Lung disease”. The conference deals with re-emerging of TB and Lung diseases
& explore new ideas/concepts on a global scale to reduce the airborne
disease and the topics include complications, treatment and therapies for lung
infections and tuberculosis, Present
scenario and risk factor of infection, Clinical trials in respiratory diseases,
TB Education and Research.
It
provides a platform for refreshing your knowledge and forecast future
developments in clinical research. This conference will offer you plenty of
opportunities to meet world’s leading scientists and researchers.
Annual summit
on Tuberculosis and Lung disease is best source for business network expansion;
we also invite worldwide pharmacy, life science and research laboratory industries
as sponsors and exhibitors.
We are
excited to meet you in Atlanta at our conference meet & we hope you will
join us at our scientific meet to expand your knowledge and move forward in
your research.
Sessions/ Tracks
Track 01: Mycobacterial infections
Tuberculosis
is a chronic inflammatory infectious disease caused by the bacteria, Mycobacterium tuberculosis. Tuberculosis
generally affects the lungs, but can even affect other parts of the body. Most
infections are asymptomatic, known as latent tuberculosis. About 10% of latent
infections progress to active disease, if left untreated, mostly kills about
half of those infected. Symptoms of active TB are chronic cough with
blood-containing sputum, night sweats, one weight loss and fever. Infection of
other organs can cause a wide range of symptoms including bones and joint
pains, chest pain, neurological disorders and chronic pulmonary or respiratory
distress etc.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 02: Epidemiology of the Disease
Tuberculosis
epidemiology is the field of science that is concerned with the study of health
and disease within populations and the various factors that lead to these
conditions, with a goal of preventing the spread of disease. One-third of the
world's population has been infected with M.
tuberculosis. 13.7 million Chronic active cases, were reported by 2007 and
8.8 million new cases were estimated in 2010 and 1.45 million deaths, are often
noted in developing countries. Out of
these, 0.35 million deaths occur in those co-infected with HIV. In 2012, around
450,000 people developed MDR-TB. TB incidence varies with age. In Africa, TB
chiefly affects adolescents and young adults. However, in United States, TB has
gone from high to low incidence, where TB is mainly a disease of older people,
or of the immunosuppressed.
Since
1985, Lung cancer has been the most common cancer in the globe. Worldwide, lung
cancer, new cancer diagnosis (134 thousand people and 12.4% of new cancer
patients) and cancer fatalities (1,180,000 deaths, 17.6% total cancer deaths).
COPD is the fourth leading cause of death in the United States and is related
to age. Lung cancer increases with age, especially after age 60. The average
age of patients diagnosed with lung cancer is 70 years.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 03: Genetics of M.
tuberculosis
In 1998,
the genome of the H37Rv strain was published. The size of the genome is 4
million base pairs, and has 3959 genes, out of these 40% of genes have their
function characterised and another 44% are postulated with possible functions.
Six pseudo genes are present within the genome.
Genome
contains 250 genes involved in fatty acid metabolism, with 39 of these involved
in the polypeptide metabolism generating the waxy coat. Such vast numbers of
conserved genes show the revolutionary importance of the waxy coating to
pathogen survival. M. tuberculosis
can grow on the lipid cholesterol as a sole source of carbon, as genes involved
in the cholesterol use pathways that have been important during various stages
of the infection with tuberculosis. 10% of the coding genes are taken up by the
amino acids that encode acidic, glycine-rich proteins. These proteins have a
conserved N-terminal motif, deletion of which leads to impaired growth in
granulomas and macrophages.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 04: Pulmonary Diseases and Therapeutics
Advanced
diagnostic techniques such as X-ray and echocardiography is used to diagnose lung
diseases and lung function tests (PFT) is another test to determine lung cancer
disease. This is a medical process involving the pleural cavity and other
thoracic internal examination, biopsy and resection of the disease or mass.
Thoracoscopy may be sedation under general anesthesia or local anesthesia.
Surgical biopsy is a better way to diagnose lung cancer standards. Must wear
appropriate masks & monitor exposure and in some working environments it is
important to take precautions. Chronic obstructive pulmonary disease is a
gradual process that causes difficulties in the death of respiratory failure or
its associated lung disease (including respiratory arterial disease, lung
cancer, stroke and smoking cessation) and is the process of stopping smoking.
Tobacco contains nicotine, which is addictive; in the process of smoking
cessation, can be controlled by vaccination and prophylaxis.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 05: Lung infection
A Lung
infection affects lungs, either in the larger airways (bronchitis) or in the
smaller air sacs (pneumonia). There is a build-up of pus and fluid (mucus), and
the airways become swollen, making it difficult for to breathe. Chest
infections can affect people of all ages. Young children and the elderly are
most at risk, as well as people who are ill and smokers. A chest infection can
be serious for these people.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 6: Vaccines & Immunization
As of
2011, the only available vaccine is Bacillus Calmette-Guérin (BCG), is a
vaccine for (TB) tuberculosis disease. Many people have been BCG-vaccinated.
BCG is primarily used as vaccine in many countries with a high aid for
preventing TB as childhood tuberculous meningitis and miliary disease.
Tuberculosis can be treated by taking several drugs for 6 to 9 months. There are 10 drugs presently approved by FDA
(U.S. Food and Drug Administration) for treating TB. Out of the approved drugs,
the first-line anti-TB agents that form the basis of treatment regimens
include: isoniazid, pyrazinamide rifampin, ethambutol, streptomycin. Once the
TB patient is known to be fully susceptible to ethambutol or streptomycin, it
can be discontinued.
Directly
observed therapy (DOT) is mainly recommended for all the patients. With DOT
treatment, patients with the above regimens can shift to 2 to 3 times per week
dosage after an initial 2 weeks of daily dosing. Patients on twice-weekly
dosing should not miss any doses. Require daily therapy for patients on
self-administered medication.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 7: TB Clinical Trials
Clinical
trials are concerned with diagnosis and treatment of the disease. The
development of drug-resistant TB (XDR-TB) and multidrug-resistant TB (MDR-TB)
are extensively a rising global health problem. A recent advance in the
progress of new drugs & regimens provides hope that may be well effective,
tolerated and shorter-duration treatment for tuberculosis will become
available. During clinical trials they promote research within local TB control
programs through association on clinical research of importance to public
health settings, and to provide a platform for international collective
research of consequence to both domestic and universal TB control.
Rapid
urine-based screening for Tuberculosis in hospitalised patients in Africa to
reduce AIDS-related mortality. Thibela TB is the mass screening and treatment
plan in mining communities, The ZAMSTAR trial is the community TB testing and
counselling, Diabetes correlated with increased risk of TB in the United
Kingdom are some of the latest clinical trials or the projects going-on to
reduce the risk of Tuberculosis.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 8: Resistance to TB Drugs
Multidrug-resistant
TB (MDR-TB) begins when an antibiotic fails to eradicate all the bacteria that
it targets, with the surviving bacteria producing resistance to that antibiotic
and usually others at the same time. Primary Multidrug resistant, MDR-TB occurs
in patients who was not earlier been infected with TB but who became infected
with a strain which is resistant to the treatment. Acquired multidrug
resistance for TB occurs in patients during treatment with a drug regimen that
is not competent of killing the particular strain of TB with which they have
been infected. MDR-TB requires treatment with second-line drugs, often four or
more anti-TB drugs for a minimum of 6 months and a maximum for 18–24 months, if
rifampin resistance has been identified in the specific strain of TB with which
the patient has been infected. Under ideal program conditions, MDR-TB cure
rates can approach 70%. In general, second-line drugs are less effective, more
toxic and much more expensive than first-line drugs.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 9: TB Co-infections
TB and
HIV co-infection is that where people have both, either latent or active TB
disease and also HIV infection. In addition to HIV infection is speeding up the
progress from latent TB infection to active TB disease, in accordance TB
bacteria also enhance the progression of HIV infection. Than many other
opportunistic infections, TB occurs earlier in the course of HIV infection. In
co-infected individuals, the risk of death is also twice that of HIV infected
individuals without TB, even when antiretroviral therapy and CD4 cell count are
taken into account. The provision of anti TB drug therapy and HIV
antiretroviral treatment at the same time involves a number of potential
difficulties including: A high pill burden, Drug – drug interactions,
Cumulative drug toxicities.
TB and
Diabetes co-infection: Poorly controlled diabetes can lead to numerous
complications, including neuropathy, vascular disease, and increased
susceptibility to infection. Diabetes may also lead to increased susceptibility
to the disease via multiple mechanisms that are caused by M. tuberculosis.
There are
even other co-infections with Tuberculosis such as malaria, Typhoid fever,
Dengue, hepatitis.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 10: TB diagnosis/ Prevention & Treatment
TB
diagnosis includes microbiological studies
such as sputum, alternative sampling, PCR.
Immunological test involves ALS assay, transdermal patch, tuberculin
skin test, mantoux skin test, heaf test, CDC classification of tuberculin
reaction, BCG vaccine and tuberculin skin test, Adenosine deaminase, Nucleic acid
amplification tests (NAAT), Full blood count & Interferon-? release assays.
TB
prevention and control efforts depend primarily on the vaccination of infants
and the detection & treatment of active cases. The World Health
Organization (WHO) has achieved some success with rapid diagnostics and
improved treatment regimens. US Preventive Services Task Force (USPSTF)
endorses screening those who are at high risk for latent tuberculosis with
either mantoux tuberculin skin tests or interferon- ? release assays. Prevention
of TB consists of two main parts. The first part of preventing TB is to cease
the transmission of tuberculosis from one person to another. This can be done
firstly, by identifying people with active TB infection, and then curing them
by providing the drug treatment. With the provision of proper TB therapy
someone with TB will not be infectious very quickly, and so cannot spread the
disease to others. The second main part of preventing TB is to prevent people
with latent TB infection from developing active infectious TB disease.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 11: Zoonotic TB
Mycobacterium bovis is the main causative agent of bovine tuberculosis
(BTB) that causes zoonotic tuberculosis (TB) in humans. Bovine TB is mostly
acquired from domestic animals and their products, in which cattle’s are the
major reservoir. The disease results in huge economic loss, particularly in
urban and per-urban cross breed dairy cattle due to mortality, low productivity
and carcass condemnation as well as trade restrictions of live animals,
products and by products of animals. To prevent and control zoonotic TB, veterinary
sectors must be cross sectored in controlling the disease
in its animal reservoir, developing diagnostic tools for diagnosing M. bovis, strengthening surveillance
systems and assessing economic impact.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 12: Lung Cancer
Lung cancer is currently the leading cause of cancer-related deaths in men and women in the world. Lung cancer-related trends have been mainly related to smoking over the past several decades. In 2015, the American Cancer Society handles 221,200 new cases, diagnosed as 158,040 deaths due only to lung cancer. Risk factors for lung cancer are primarily smoking and air pollution. According to the doctor's suggestion, there are no symptoms associated with the first stage of lung cancer. According to researchers' research, lung cancer mortality rate is not improved at the time of diagnosis and most lung cancer progresses to advanced stage.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 13: COPD
COPD is a
disease involving airway inflammation and thickening. It also involves the destruction of
oxygen-exchanged lung tissue. The Global Initiative for Chronic Obstructive
Pulmonary Disease is described as "preventable and treatable disease,
characterized by an incompletely reversible airflow limitation, which is
usually progressive and is associated with an abnormal inflammatory response to
harmful particles or gases. This gradual and relentless loss of lung disease is
caused by emphysema caused by the destruction of the lung parenchyma. Smoking
(long term smokers), chronic bronchitis, genetic factors (genes) and due to
chronic inflammation and fibrosis as well as elasticity The resulting loss of
small airway narrows, which leads to gradual airflow limitation, air capture,
and further shortages of breathing in motion.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections Conference
Track 14: Asthma & Pneumonia
Asthma is
a chronic disease that makes lungs harder and affects the airways that carry
air to and from the lung which leads to swelling or inflammation of the airway
wall. This swelling or inflammation makes the airways extremely sensitive to
irritations and increases your susceptibility to an allergic reaction. As
inflammation causes the airways to become narrower, less air can pass through
them, both to and from the lungs which makes difficult to breathe. Thus the
patience suffers from symptoms like wheezing (a hissing sound while breathing),
chest tightness, breathing problems, and coughing.
Tuberculosis Conference | Lung Conference | Asthma Conference | Pneumonia Conference | Pulmonary Conference | Respiratory infections
Conference
Market Analysis
Market Analysis:
Scope:
The scope of TB & lung research
involves developing molecular techniques for diagnosis of even very minute levels
of the organism which ultimately contributes to the more affordable molecular
tests or next-generation assays for latent/ Active TB or MDR-TB and in turn
this is related to the development and safety of public health. The vision behind this world congress is to build a worldwide stage for pulmonologist,
Lung care and TB specialists and analysts from widely acclaimed foundations to
share and trade new clinical examinations and progressions in dealing with respiratory
diseases. The scientific conferences include oral and poster presentations,
seminars, and workshops from the professionals working within the field of
medicine.
Value of TB & Lung Research:
TB incidence in the United
States during 2013–2015 remained approximately 3.0 cases per 100,000
persons. After 2 decades of progress toward tuberculosis elimination with
annual decreases of 0.2 cases per 100,000 persons have been reported. Initial
data stated to the National Tuberculosis Surveillance System display that TB
incidence among U.S.-born persons (1.2 cases per 100,000) has remained
approximately 13 times the foreign-born persons incidence in the U.S (15.1
cases per 100,000). Proceeding to the progress towards TB elimination will require
amassing of efforts both in the U.S and other parts of the world, including,
strengthening systems to stop TB transmission in the United States and all
around the universe, increasing U.S. efforts to detect and treat latent TB
infection, and accelerating reductions in TB globally, particularly in the
countries of origin and with highest reported cases.
Health
departments of Columbia (DC) verified TB cases in the 50 states and District
electronically report that meet the Council of State, CDC and Territorial
Epidemiological case defines to the National Tuberculosis
Surveillance System. Reports involve the patient’s medical and demographic
information, clinical information and social risk factors for TB, and about the
TB case. CDC calculates state and overall national TB incidence by using July 1
midyear population estimates from the U.S. Census Bureau. The Current
Population Survey provides the population figures for incidence according to
race/ethnicity and national origin. TB case tally and incidence during 2015 as
per 100,000 population and % change from 2014 were determined for 50 states and
for each census division.
Major TB & Lung Associations
in US & Canada:
·
Abbott
·
AstraZeneca
·
Bayer
HealthCare AG
·
Bill
& Melinda Gates Foundation
·
Eli Lilly
·
GlaxoSmithKline
·
Infectious
Disease Research Institute
·
Merck
& Co.
·
National
Institute of Allergy and Infectious Diseases
·
Pfizer
·
Sanofi
·
Texas
A&M University
·
Weill
Cornell Medical College
Major Funding Bodies for TB & Lung Research
around the Globe:
Biotechnology and Biological Sciences Research
Council
Bill & Melinda Gates Foundation
https://www.gatesfoundation.org/
The Royal Society
The Gatsby Charitable Foundation
European Molecular Biology Organisation
European Research Council
European Science Foundation
Public health agency of Canada
https://www.canada.ca/en/public-health.html
Stop TB Partnership
World Health Organization
Future Prospects:
The
evolution of global TB
control policies, including DOTS (directly observed therapy, short course)
and the Stop TB Strategy, and assess whether the challenges and obstacles faced
by the public health
community worldwide in developing and implementing this strategy can aid
future action towards the elimination of TB. Research in TB diagnosis
and pulmonary genomics is centralized on the cellular and genetic control of TB & lung cancer.
Complexities
emerging due to various associated infections and disease conditions, there is
a furious need for further research in the field. Be it the better medication
and care or better resistance management, proper diagnostics holds the key to
success. The development of drug-resistant
TB (XDR-TB) and multidrug-resistant TB (MDR-TB) are extensively a rising global
health problem. A recent advance in the progress of new drugs & regimens
provides hope that may be well effective, tolerated, and shorter-duration
treatment for tuberculosis will become available.
Major challenges for the next decade include:
- Mass screening and treatment
plan in mining communities
- Managing drug-resistant
tuberculosis, Lung cancer, asthma and pneumonia in children
- Exploration of
private-public sector in association to manage respiratory infections.
- The Immune
Reconstitution Inflammatory Syndrome (IRIS)
- Research into
effectiveness of programmes and means of collaboration with HIV/AIDS
programmes.
- Priority
research in the area of TB treatment for people living with HIV.
- Testing and Development of
new drugs, with shorter durations of treatment.
- Improvement for cheap,
easily applied diagnostic methods
- Prospects for
new antitubercular agents and vaccines
- Prevention of risk factors
and side
effects
- An adequately
resourced, well organised tuberculosis programme should be a priority in
developing and developed countries.
- Effective and preventive therapy
for drug resistance patients.
- Examining ways of improving
concordance with treatment among doctors and patients.
- Further exploration of
public-private sector partnerships in managing Asthma, pneumonia and tuberculosis.
- Develop and
validate biomarkers and proxy endpoints that predict efficiency and
thereby shorten clinical trial duration.